Latest News

Immutep (ASX:IMM) has announced "mature positive efficacy" data from its TACTI-mel Phase 1 clinical study combining its lead product candidate, eftilagimod alpha, with MSD's KEYTRUDA (pembrolizumab) in metastatic melanoma.

New Zealand headquartered regenerative medicine company Aroa Biosurgery has announced the appointment of experienced US-based executive, Brad Adams, to the new position of vice president, commercial.

“The R&D tax incentive provides significant leverage to the Pharmaxis research team’s development of new drugs for inflammation and fibrotic diseases," said CEO Gary Phillips.

Clinical stage cannabinoid company Botanix Pharmaceuticals (ASX:BOT) has been awarded a new Innovation Connections Grant by federal agency AusIndustry.

AusBiotech warmly welcomes Dr Peter French as their new Industry Development Manager, NSW - an indication of its continued support of life sciences across Australia. Dr French has strong industry connections and will be a key part of growing the NSW life sciences industry.

Australian biopharmaceutical company Opthea (ASX:OPT) has announced the presentation of additional data from the recently completed 366 patient Phase 2b randomised controlled wet AMD study of OPT-302 with Novartis' PBS-listed LUCENTIS (ranibizumab) compared to LUCENTIS alone.

It was with sadness that AusBitoech acknowledges the passing of Dr John Holaday (1945-2019).

Two Australian scientists have each been awarded five year $1.25 million CSL Centenary Fellowships for research looking at ways to improve treatments for two of the world’s biggest health challenges - malaria and cancer.

"Breakthroughs in this area will provide significant benefits to the medical treatment Australians receive as well as providing new business opportunities," said education minister Dan Tehan.

Australian biopharmaceutical company AdAlta (ASX:1AD) has appointed a senior and experienced industry executive as its new CEO and managing director.

“The FDA approval of SCENESSE as a new molecular entity and medical innovation is memorable for this Company and for the Australian life science sector," CEO Dr Philippe Wolgen.

Medicinal cannabis company Zelda Therapeutics has announced a "merger of equals" with privately-held US-based counterpart Ilera Therapeutics.